United Therapeutics Corp. (NASDAQ:UTHR) on Monday shared results from its phase 1 study of miroliverELAP, an external liver assist product, in patients with acute forms of liver failure.
Developed by Miromatrix Medical, a wholly owned subsidiary of United Therapeutics, miroliverELAP consists of an external blood circuit and a single-use bioengineered liver sustained outside of the human body to provide temporary liver support to patients.
The bioengineered liver is manufactured by seeding a decellularized porcine liver scaffold with allogeneic human endothelial cells and human liver cells isolated from donated human livers.
The donated human livers are not suitable for transplantation and are provided by organ procurement organizations.
Positive Phase 1 Results for MiroliverELAP
In the study, five patients with acute liver failure who were not candidates for a liver transplant were treated with miroliverELAP for at least 44 hours.
The treatment met its primary endpoint of survival during the study, with no unexpected serious adverse events reported over a subsequent 32-day follow-up period.
The positive results highlight the potential of miroliverELAP to provide critical liver support for patients facing dire circumstances due to acute liver failure.
Full study results will be presented and published in the second half of 2026.
UTHR Stock Technical Indicators Overview
United Therapeutics’ stock is currently trading 2.7% below its 20-day simple moving average (SMA) and 2.5% below its 50-day SMA, but is 3.7% above its 100-day SMA, demonstrating some longer-term strength. Shares have increased approximately 26.89% over the past 12 months and are currently positioned closer to their 52-week highs than lows.
The RSI is at 39.40, which is considered neutral territory, while MACD is below its signal line, indicating bearish pressure on the stock. The combination of neutral RSI and bearish MACD suggests mixed momentum.
- Key Resistance: $512.50
- Key Support: $470.00
Upcoming Earnings: Analysts’ EPS and Revenue Forecasts
Investors are looking ahead to the company’s next earnings report on February 25, 2026, with analysts expecting earnings per share of $6.82, up from $6.19 from the same quarter last year and revenue of $810.08 million, up from $735.90 million from the same quarter last year.
EPS Estimate: $6.82 (Up from $6.19 YoY)
Revenue Estimate: $810.08 Million (Up from $735.90 Million YoY)
Analyst Consensus: Buy Rating ($447.43 Avg Price Target)
Benzinga Edge Scores Highlight UTHR’s Strengths
Below is the Benzinga Edge scorecard for United Therapeutics, highlighting its strengths and weaknesses compared to the broader market:
- Value Rank: 61.88 — The stock is fairly valued relative to peers.
- Quality Rank: 75.91 — The company maintains a strong balance sheet.
- Momentum Rank: 86.84 — The stock is outperforming the broader market.
The Verdict: United Therapeutics’s Benzinga Edge signal reveals a strong momentum setup with a solid quality score. While the value rank suggests fair valuation, the high momentum score indicates that the stock is currently in a favorable trend.
ETFs with Significant UTHR Exposure
- Invesco S&P MidCap Quality ETF (NYSE:XMHQ): 3.55% Weight
- First Trust Health Care AlphaDEX Fund (NYSE:FXH): 2.44% Weight
- Simplify Health Care ETF (NYSE:PINK): 3.24% Weight
Price Action: UTHR stock is up 0.44% at $471 during the premarket session at the last check on Monday, according to Benzinga Pro data.
Photo via Shutterstock
Recent Comments